Vident Advisory’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
Other funds holding PCRX
Vident Advisory's PCRX Position: Q3 2026 in Review
Vident Advisory increased its Pacira BioSciences (PCRX) stake by 2.1% in Q3 2026, buying an estimated $15.8K and bringing the position to 30,779 shares worth $771K. The position accounts for 0.01% of the portfolio, ranked #1121.
Vident Advisory first reported a position in PCRX in Q3 2024 and has held it in 9 quarters since. 258 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.
- Vident Advisory held 30,779 shares of Pacira BioSciences worth $771K as of Q3 2026.
- Vident Advisory bought 622 Pacira BioSciences shares in Q3 2026, an estimated $15.8K.
- Pacira BioSciences made up 0.01% of Vident Advisory's portfolio in Q3 2026, its #1121 holding.
- Vident Advisory first reported a position in Pacira BioSciences in Q3 2024 and has held it in 9 quarters since.
- 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.
Based on Vident Advisory's 13F filing for Q3 2026, filed 16 Nov 2026.